Patient health data is at the core of almost every healthcare technology innovation. Collected and stored across computers, mobile devices, wearables, and other technologies, this data, collectively, is called real-world data (RWD). This page serves as a library of how we see RWD driving value in the cancer space.
At COTA, we curate regulatory-grade oncology RWD with the most relevance for our life sciences and provider partners, whether that involves supporting regulatory filings or research questions. We cannot unlock the full value of RWD without the highest-quality collection and curation methodology, and we are powering a revolution in the development of new cancer therapies to bring clarity to cancer care.
The right cohorts after applying inclusion/exclusion criteria at the right volumes
Representativeness across real-world and clinical trial populations
Coverage across geographies of interest
We have a responsibility to drive the use of RWD by consistently improving our data and demonstrating its utility. Our data has been used to support FDA and EMA submissions, explain care patterns, understand patient outcomes, and much more – and we anticipate the number of use cases to multiply in the coming years as RWD is explored and leveraged by more and more innovators in the industry.
Browse related research, case studies and other resources that highlight examples of how RWD is being used today.
To create targeted LLMs that are suitable for diving into health-related areas like oncology, we must choose our data carefully and get as close to the original source as possible to avoid “playing telephone” with inaccurate information that could affect drug development processes or cancer outcomes.
A panel of senior Google Cloud executives selected COTA from a pool of entries to win *2* Google Cloud Customer Awards. These awards showcase companies from around the world who are using Google Cloud technologies to improve their operations, and their social and governance efforts.
While the incidence of lung cancer is decreasing over time, and survival rates are on the rise year-over-year, there is still much to learn about how to best treat this disease – and prevent its recurrence after initial therapy.
Interested in learning more about how we can transform cancer care together?
